Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Guardant Health, Inc.    GH

GUARDANT HEALTH, INC.

(GH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Guardant Health : Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder

10/15/2020 | 04:08pm EST

Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which were sold by SoftBank Investment Advisers. The initial closing of 7,000,000 shares occurred on October 9, 2020, and the closing of the underwriter’s option to purchase additional shares occurred today.

Guardant Health did not sell any of its shares in the offering and did not receive any of the proceeds from the sale of shares in the offering by SoftBank Investment Advisers.

J.P. Morgan Securities LLC acted as sole book-running manager of the offering.

The public offering was made pursuant to an automatic shelf registration statement on Form S-3 that was filed by Guardant Health with the U.S. Securities and Exchange Commission (the “SEC”) and automatically became effective upon filing. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Source: Guardant Health, Inc.


© Business Wire 2020
All news about GUARDANT HEALTH, INC.
11/20GUARDANT HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of ..
AQ
11/17GUARDANT HEALTH, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
11/16GUARDANT HEALTH, INC. : Prices $1 Billion Convertible Senior Notes Offering
BU
11/16GUARDANT HEALTH, INC. : Announces Proposed Convertible Senior Notes Offering
BU
11/05GUARDANT HEALTH : Management's Discussion and Analysis of Financial Condition an..
AQ
11/05GUARDANT HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/05GUARDANT HEALTH : 3Q Earnings Snapshot
AQ
11/05GUARDANT HEALTH : Reports Third Quarter 2020 Financial Results
BU
10/16GUARDANT HEALTH : Announces Webcast of Third Quarter Financial Results on Novemb..
BU
10/15GUARDANT HEALTH : Announces Closing of Public Offering of Common Stock, Includin..
BU
More news
Financials (USD)
Sales 2020 285 M - -
Net income 2020 -202 M - -
Net cash 2020 1 305 M - -
P/E ratio 2020 -55,6x
Yield 2020 -
Capitalization 11 408 M 11 408 M -
EV / Sales 2020 35,5x
EV / Sales 2021 27,3x
Nbr of Employees 622
Free-Float 92,3%
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 130,78 $
Last Close Price 114,11 $
Spread / Highest target 27,1%
Spread / Average Target 14,6%
Spread / Lowest Target 5,16%
EPS Revisions
Managers
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Derek A. Bertocci Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors
1st jan.Capitalization (M$)
GUARDANT HEALTH, INC.46.03%11 292
EXACT SCIENCES CORPORATION24.60%18 325
INVITAE CORPORATION197.58%8 482
BGI GENOMICS CO., LTD.93.77%7 923
ADAPTIVE BIOTECHNOLOGIES CORPORATION55.08%6 329
IOVANCE BIOTHERAPEUTICS, INC.31.68%5 347